The RFA Ticker continues to show a big fat ZERO for ME/CFS research, but there is one interesting bit of research-related bit news. NIH has issued an updated notice about the Lipkin samples. These samples were collected as part of the Lipkin study of XMRV, and were collected from very well characterized ME/CFS patients. The notice states that NIH considers these samples to be “an extremely valuable resource,” and:
we encourage the submission of new grant applications to the NIH that involve the use of some of these specimens as part/all of a research plan on some aspect of ME/CFS. However, please note there are no set-aside funds associated with these samples. Prior to the submission of a NIH grant application utilizing these samples, interested investigators are encouraged to contact Dr. Lipkin to ensure that the proposed experimental plan meets the terms specified in obtaining informed consent from study subjects and/or other regulations.
It is astounding to me that these samples remain. Have ME/CFS investigators applied for NIH funding to use the samples and been rejected? Or are investigators simply not aware of the resource available to them? It’s a positive sign that NIH is reminding everyone about the samples, but disappointing that there are no set aside funds to support analyzing them.
- Total RFAs Issued by NIH: 140 (October 2015 to date)
- Total Dollars Committed to RFAs: $1,581,000,000 (October 2015 to date)
- Total RFAs for ME/CFS: ZERO (October 2015 to date)
|Week Beginning||RFAs Issued||Total Commitment||RFAs for ME/CFS|
If you want more background on the RFA Ticker, read the inaugural post.